Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs( )

BACKGROUND: Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-benefit ratio. Yet this combination is an important alternative for patients infected with strains of TB with complex dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Huerga, Helena, Khan, Uzma, Bastard, Mathieu, Mitnick, Carole D, Lachenal, Nathalie, Khan, Palwasha Y, Seung, Kwonjune J, Melikyan, Nara, Ahmed, Saman, Rich, Michael L, Varaine, Francis, Osso, Elna, Rashitov, Makhmujan, Salahuddin, Naseem, Salia, Gocha, Sánchez, Epifanio, Serobyan, Armine, Rafi Siddiqui, Muhammad, Grium Tefera, Dri, Vetushko, Dmitry, Yeghiazaryan, Lusine, Holtzman, David, Islam, Shirajul, Kumsa, Andargachew, Jacques Leblanc, Gamarly, Leonovich, Olga, Mamsa, Shahid, Manzur-ul-Alam, Mohammad, Myint, Zaw, Padayachee, Shrivani, Franke, Molly F, Hewison, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555840/
https://www.ncbi.nlm.nih.gov/pubmed/35243494
http://dx.doi.org/10.1093/cid/ciac176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555840/
https://www.ncbi.nlm.nih.gov/pubmed/35243494
http://dx.doi.org/10.1093/cid/ciac176

Ejemplares similares